Entire Portfolio
print

Composition of the portfolio as of June 30, 2014

Celgene   13.2%
Actelion   11.5%
Gilead   10.5%
Incyte   8.6%
Isis Pharmaceuticals   8.4%
Vertex Pharmaceuticals   4.8%
Medivation   4.2%
Alexion Pharmaceuticals   4.1%
Novo Nordisk   3.8%
Synageva BioPharma   3.4%
Swedish Orphan Biovitrum   3.0%
Regeneron Pharmaceuticals   2.4%
Pharmacyclics   2.4%
Halozyme Therapeutics   2.1%
Neurocrine Biosciences   1.7%
Alnylam Pharmaceuticals   1.4%
Puma Biotechnology   1.4%
Immunogen   1.4%
Radius Health   1.3%
Glenmark Pharmaceuticals   1.3%
Lupin   1.1%
Ipca Laboratories   1.0%
Theravance   1.0%
Agios Pharmaceuticals   0.8%
Clovis Oncology   0.8%
Tesaro   0.8%
Bavarian Nordic   0.8%
Infinity Pharmaceuticals   0.7%
Endocyte   0.6%
Achillion Pharmaceuticals   0.5%
Theravance Biopharma   0.3%
Probiodrug 1)   0.3%
Strides Arcolab   0.1%
     
Radius Health Warrants 23.04.2018   <0.1%
Radius Health Warrants 19.02.2019   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Optimer   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Trius   0.0%
     
Total Securities   CHF 2 432.8 mn
     
Other assets   CHF 44.7 mn
Other payables   CHF (186.3) mn
     
total shareholder's equity   CHF 2 291.2 mn
Treasury shares (in % of company) 2)   4.4%

 

1) Unlisted company

2) Correspond to the total of all own shares held including the second trading line